 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
MiNK Therepeutics
INKT
conference date: November 14, 2024 @ 5:30 AM Pacific Time
MiNK Therapeutics: iNKT Therapy Data Should Drive Stock Price Up [March 25, 2023 at Seeking Alpha]
MiNK Therapeutics Undervalued Given Platform Potential [December 5, 2022 at Seeking Alpha]
MiNK Therapeutics a Bargain for Cell Therapies [June 23, 2022 at Seeking Alpha]
| 2024 | |||
| Mink Therapeutics Q1 2024 |
Mink Therapeutics Q2 2024 |
Mink Therapeutics Q3 2024 |
|
| May 14, 2024 | Aug. 13, 2024 | Nov. 14, 2024 | |
| 2023 | |||
| Mink Therapeutics Q1 2023 |
Mink Therapeutics Q2 2023 |
Mink Therapeutics Q3 2023 |
Mink Therapeutics Q4 2023 |
| May 11, 2023 | Aug. 10, 2023 | Nov. 9, 2023 | Mar. 21, 2024 |
| 2022 | |||
| Mink Therapeutics Q1 2022 Press Release |
Mink Therapeutics Q2 2022 |
Mink Therapeutics Q3 2022 |
Mink Therapeutics Q4 2022 |
| May 10, 2022 | Aug. 9, 2022 | Nov. 3, 2022 | March 21, 2023 |
MiNK Therapeutics (INKT) is a clinical-stage biotechnology company specializing in cell therapies for cancers and immunological diseases.
Note: Agenus (AGEN) owns a majority of the shares of INKT common stock, per 2021 10-K
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALLO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BLRX |
| BLUE |
| BMY |
| CDTX |
| CLDX |
| FATE |
| GILD |
| GLYC |
| ILMN |
| INCY |
| INO |
| IONS |
| MCHP |
| MRNA |
| PLX |
| REGN |
| RNA |
| SAGE |
| SANA |
| SYRS |
| TSVT |
| VRTX |
| VSTM |
| WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2024 William P. Meyers